{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+Lymphomas", "query": { "condition": "High Grade Lymphomas" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 262, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Grade+Lymphomas&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:13:23.700Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00004061", "title": "Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Oral Complications" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 111, "start_date": "1999-05", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2013-06-26", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004061" }, { "nct_id": "NCT00003269", "title": "Amifostine Followed by High Dose Chemotherapy in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer", "Drug/Agent Toxicity by Tissue/Organ", "Lung Cancer", "Lymphoma", "Ovarian Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Scripps Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 20, "start_date": "1998-02", "completion_date": "2001-01", "has_results": false, "last_update_posted_date": "2011-01-10", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "La Jolla, California", "locations": [ { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003269" }, { "nct_id": "NCT00004039", "title": "Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "recombinant interferon alfa", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Hoag Memorial Hospital Presbyterian", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "1998-06", "completion_date": "2000-01", "has_results": false, "last_update_posted_date": "2015-08-19", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Newport Beach, California", "locations": [ { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004039" }, { "nct_id": "NCT00143884", "title": "Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma, Low-Grade", "Lymphoma, Non-Hodgkin's", "Multiple Myeloma", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Reduced intensity conditioning", "type": "PROCEDURE" }, { "name": "Prophylactic donor leukocyte infusions", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-04-23", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00143884" }, { "nct_id": "NCT02706405", "title": "JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma" ], "interventions": [ { "name": "Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Fludarabine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-11-15", "completion_date": "2021-05-28", "has_results": true, "last_update_posted_date": "2022-08-24", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02706405" }, { "nct_id": "NCT07098364", "title": "ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent Grade 3b Follicular Lymphoma", "Recurrent High-Grade B-Cell Lymphoma", "Recurrent Indolent B-Cell Non-Hodgkin Lymphoma", "Recurrent Primary Mediastinal Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory Grade 3b Follicular Lymphoma", "Refractory High-Grade B-Cell Lymphoma", "Refractory Indolent B-Cell Non-Hodgkin Lymphoma", "Refractory Primary Mediastinal Large B-Cell Lymphoma" ], "interventions": [ { "name": "Vevoctadekin", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lisocabtagene Maraleucel", "type": "BIOLOGICAL" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Lymphodepletion Therapy", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2025-12-27", "completion_date": "2043-10-04", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT07098364" }, { "nct_id": "NCT03103971", "title": "huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Adult Acute Lymphoblastic Leukemia", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent B Acute Lymphoblastic Leukemia", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "Refractory B Acute Lymphoblastic Leukemia", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements" ], "interventions": [ { "name": "Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2017-11-03", "completion_date": "2024-03-23", "has_results": false, "last_update_posted_date": "2024-04-10", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03103971" }, { "nct_id": "NCT06815029", "title": "Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Astrocytoma, IDH-Mutant, Grade 3", "Recurrent Astrocytoma, IDH-Mutant, Grade 4", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Intracranial Catheter Placement", "type": "PROCEDURE" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Resection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-06-17", "completion_date": "2030-10-11", "has_results": false, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06815029" }, { "nct_id": "NCT00003883", "title": "Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "fluconazole", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 578, "start_date": "1998-10", "completion_date": "2002-07", "has_results": false, "last_update_posted_date": "2010-04-02", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003883" }, { "nct_id": "NCT05660395", "title": "A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma", "High-grade B-cell Lymphoma" ], "interventions": [ { "name": "Loncastuximab Tesirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ADC Therapeutics S.A.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2023-08-28", "completion_date": "2027-04-05", "has_results": false, "last_update_posted_date": "2025-07-16", "last_synced_at": "2026-05-22T04:13:23.700Z", "location_count": 1, "location_summary": "Lynwood, California", "locations": [ { "city": "Lynwood", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05660395" } ] }